GLP-1 agonists including semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) have been approved by the Food and Drug Administration for chronic weight management in adults with obesity or those who are overweight and have at least 1 weight-related condition. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.